Over the last three decades, the evidence on how to best treat the cognitive and non-cognitive symptoms of patients with ...
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback